Evolving Role of CGM in Diabetes Care: What’s New in 2026

This activity was originally presented at the 2026 Diabetes Day of Education.

Program Description

With over 38 million Americans now living with diabetes and continuous glucose monitoring (CGM) usage increasing more than twofold in the last decade, the management of diabetes as a chronic condition has rapidly shifted from reactive fingersticks to proactive, real-time data integration. Despite these technological strides, pharmacists and pharmacy technicians face significant challenges, including navigating complex administrative barriers to device access and ensuring that diverse patient populations can effectively utilize these tools to avoid diabetes-related complications. Pharmacists have become essential partners in diabetes care, facilitating the implementation of clinical guidelines and providing individualized care. This program will review the prevalence of diabetes before diving into modern glycemic management strategies featuring CGM devices, with attention on the different features of available prescription CGM devices in the community setting. In addition to highlights of the 2026 ADA Standards of Care, the session will review critical technological updates, such as the transition to updated CGM systems, the integration of CGM with automated insulin delivery (AID) systems, and the development of continuous ketone monitoring, while also providing practical updates on access and coverage considerations. By examining real-world use and strategies to overcome utilization barriers, this session will empower pharmacists and pharmacy technicians to improve their decision-making and better support people living with diabetes in achieving optimal metabolic health.

Target audience: Community pharmacists and pharmacy technicians

Type of activity: Application

Release date: May 22, 2026

Expiration date: May 22, 2027

Learner level: Intermediate, Foundational

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, pharmacists will be able to:

• Examine the current evidence-based guidelines for the treatment and management of diabetes
• Explain common diabetes-related complications and their impact on patient morbidity and quality of life, emphasizing how technology can help mitigate these risks
• Explore strategies to overcome clinical and administrative barriers to continuous glucose monitor access and utilization across diverse patient populations

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-147-H01-P and 0290-0000-26-147-H01-T. The activity is available for CE credit through May 22, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: MiniMed, Tandem

Speakers Bureau: Abbott, CeQur, Dexcom, Insulet, Lilly, Novo Nordisk, Sanofi, Sequel Pharma

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms